<DOC>
	<DOC>NCT02031419</DOC>
	<brief_summary>First study, at multiple clinical centers, exploring the effects of different combinations of compounds (CC-122, CC-223 ,CC-292 and rituximab) to treat Diffuse Large B Cell Lymphoma (DLBCL)</brief_summary>
	<brief_title>Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma</brief_title>
	<detailed_description>Study CC-122-DLBCL-001 is a Phase 1b dose escalation and expansion clinical study of CC 122, CC-223 and CC-292 administered orally as doublets with or without rituximab, in subjects with relapsed/refractory DLBCL who have failed standard therapy.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Biopsy proven Diffuse large Bcell lymphoma (DLBCL) (including transformed low grade lymphoma) Relapsed or refractory to prior standard treatment regimens At least one site of measurable disease Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1. Subjects must have the following laboratory values: Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L or ≥ 1.0 x 109/L (with bone marrow involvement with DLBCL) Hemoglobin (Hgb) ≥ 8 g/dL. Potassium within normal limits Asparate Aminotransferase/Serum Glutamic Oxaloacetic Transaminase (AST/SGOT) and Alanine Aminotransferase/Serum GlutamicPyruvic Transaminase (ALT/SGPT) ≤ 2.5 x Upper Limit of Normal (ULN) or ≤ 5.0 X ULN if liver tumor is present. Serum bilirubin ≤ 1.5 x ULN. Estimated serum creatinine clearance of ≥ 50 mL/min Subjects must have the following laboratory values: Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L without growth factor support for 7 days (14 days if subject received pegfilgrastim). Males enrolled into treatment arms receiving CC122 must: Agree to abstain from donating sperm while taking IP and for at least 3 months following discontinuation of IP Symptomatic central nervous system involvement. Known symptomatic acute or chronic pancreatitis. Persistent diarrhea or malabsorption despite medical management. Peripheral neuropathy ≥ grade 2 Impaired cardiac function or clinically significant cardiac diseases Subjects with diabetes on active treatment (for subjects treated on CC223 containing arms only) Prior autologous stem cell transplant (ASCT) ≤ 3 months before first dose. Prior allogeneic stem cell transplant with either standard or reduced intensity conditioning. Prior systemic cancerdirected treatments or investigational modalities ≤ 5 half lives or 4 weeks prior to starting study drugs, whichever is shorter. Subjects who have undergone major surgery ≤ 2 weeks prior to starting study drugs. Women who are pregnant or breast feeding. Adults of reproductive potential not willing to employ two forms of birth control. Subjects with known HIV infection, chronic active hepatitis B or C virus (HBV/HCV) infection. Subjects with treatmentrelated myelodysplastic syndrome. History of concurrent second cancers requiring active, ongoing systemic treatment. Prior treatment with a dual mTORC1/mTORC2 inhibitor (CC223 arms only) or BTK inhibitor (PCI32765) (CC292 arms only). [Prior treatment with rapamycin analogues, PI3K or AKT inhibitors, lenalidomide and rituximab are allowed].</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CC-122</keyword>
	<keyword>CC-223</keyword>
	<keyword>CC-292</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Diffuse Large B-Cell Lymphoma</keyword>
</DOC>